MannKind Gelecekteki Büyüme

Future kriter kontrolleri 4/6

MannKind kazanç ve gelirinin sırasıyla yıllık 39.7% ve 13.9% oranında artması tahmin edilirken, EPS'nin yıllık 38.7% oranında büyümesi bekleniyor.

Anahtar bilgiler

39.7%

Kazanç büyüme oranı

38.7%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.7%
Gelir büyüme oranı	13.9%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	18 Dec 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets

Dec 17

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Oct 03

MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Sep 18

Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

Jul 17

MannKind Outperforms As Tyvaso DPI Captures Market Share

May 15

This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

Mar 03

MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Mar 02

MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

Jan 27

Mannkind Corporation: Ready For Your Biotech Portfolio

Sep 01

New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

Aug 19

MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed

Aug 09

MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?

Feb 25

MannKind: A Promising Player In The Inhalable Insulin Market

Feb 08

US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Aug 14

Lytham Partners Summer 2021 Investor Conference

Jun 14

MannKind (MNKD) Investor Presentation - Slideshow

Jun 04

MannKind reduces debt by $49.5M and restructures remaining obligations

Apr 26

Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?

Feb 22

MannKind to co-promote Thyquidity

Dec 17

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:MNKD - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	385	102	157	71	4
12/31/2025	332	63	122	61	4
12/31/2024	284	28	94	37	4
9/30/2024	267	22	29	42	N/A
6/30/2024	248	12	18	41	N/A
3/31/2024	225	8	3	40	N/A
12/31/2023	199	-12	-8	34	N/A
9/30/2023	177	-31	-32	10	N/A
6/30/2023	158	-47	-57	-27	N/A
3/31/2023	128	-71	-72	-61	N/A
12/31/2022	100	-87	-88	-81	N/A
9/30/2022	76	-98	-98	-91	N/A
6/30/2022	66	-88	-89	-78	N/A
3/31/2022	70	-94	-83	-67	N/A
12/31/2021	75	-81	-73	-62	N/A
9/30/2021	81	-79	-60	-49	N/A
6/30/2021	75	-86	-54	-47	N/A
3/31/2021	66	-61	-35	-30	N/A
12/31/2020	65	-57	-33	-28	N/A
9/30/2020	63	-45	-34	-33	N/A
6/30/2020	62	-44	-73	-72	N/A
3/31/2020	62	-46	-91	-88	N/A
12/31/2019	63	-52	-91	-88	N/A
9/30/2019	63	-47	-61	-58	N/A
6/30/2019	53	-61	-22	-20	N/A
3/31/2019	42	-71	-28	-28	N/A
12/31/2018	28	-87	-38	-38	N/A
9/30/2018	16	-110	-93	-93	N/A
6/30/2018	13	-119	N/A	-102	N/A
3/31/2018	12	-131	N/A	-95	N/A
12/31/2017	11	-117	N/A	-65	N/A
9/30/2017	20	-31	N/A	-48	N/A
6/30/2017	180	129	N/A	-47	N/A
3/31/2017	178	134	N/A	-39	N/A
12/31/2016	175	126	N/A	-78	N/A
9/30/2016	162	-205	N/A	-88	N/A
6/30/2016	N/A	-364	N/A	-85	N/A
3/31/2016	N/A	-363	N/A	-91	N/A
12/31/2015	N/A	-368	N/A	-57	N/A
9/30/2015	N/A	-128	N/A	-70	N/A
6/30/2015	N/A	-133	N/A	50	N/A
3/31/2015	N/A	-177	N/A	44	N/A
12/31/2014	N/A	-198	N/A	4	N/A
9/30/2014	N/A	-216	N/A	6	N/A
6/30/2014	N/A	-230	N/A	-127	N/A
3/31/2014	N/A	-203	N/A	-134	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MNKD 'nin tahmini kazanç büyümesi (yıllık 39.7% ) tasarruf oranının ( 2.6% ) üzerindedir.

Kazançlar ve Piyasa: MNKD şirketinin kazançlarının (yıllık 39.7% ) US pazarından (yıllık 15.3% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: MNKD şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: MNKD şirketinin gelirinin (yıllık 13.9% ) US pazarından (yıllık 9.1% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: MNKD şirketinin gelirinin (yıllık 13.9% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MNKD 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/18 10:08
Gün Sonu Hisse Fiyatı	2024/12/18 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

MannKind Corporation 26 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Thomas Russo	Baird
Stephen V. Byrne	BofA Global Research
null null	BTIG

MannKind Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 9.8% to US$7.25

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 8.1% to US$6.67

Consensus forecasts updated

Price target decreased to US$5.50

Consensus estimates of losses per share improve by 15%

Recent updates

MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

MannKind Corporation Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

MannKind Corporation to Report Q3, 2024 Results on Nov 07, 2024

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Mannkind Corporation Announces Top-Level 30-Week Results from Its Phase 4 Inhale-3 Study

MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

MannKind Corporation Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Mannkind Corporation Announces Board Changes, September 30, 2024

MannKind Corporation to Report Q2, 2024 Results on Aug 07, 2024

Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

MannKind Corporation Announces Positive 17-Week Results from the INHALE-3 Study

MannKind Outperforms As Tyvaso DPI Captures Market Share

New major risk - Financial position

MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

MannKind Corporation to Report Q1, 2024 Results on May 08, 2024

MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases

MannKind Corporation, Annual General Meeting, May 15, 2024

MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024

MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024

MannKind Corporation Announces INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps

This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Full year 2023 earnings: EPS and revenues exceed analyst expectations

MannKind Corporation to Report Q4, 2023 Results on Feb 27, 2024

MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®

MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation

MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking

CEO & Director notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

MannKind Corporation Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living with Type 1 Diabetes

MannKind Corporation to Report Q3, 2023 Results on Nov 07, 2023

Price target increased by 9.8% to US$7.25

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

MannKind Corporation to Report Q2, 2023 Results on Aug 07, 2023

Mannkind Corporation Launches Inhale-3 Study to Address the Most Important Unmet Need in Adults Living with Type 1 Diabetes (T1d)

CEO & Director notifies of intention to sell stock

Dr. Burkhard Blank Joins MannKind Corporation as Executive Vice President of Research & Development and Chief Medical Officer

Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 8.1% to US$6.67

Full year 2022 earnings: EPS misses analyst expectations

MannKind Corporation to Report Q4, 2022 Results on Feb 23, 2023

MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

MannKind Corporation Announces its Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Mannkind Corporation Announces Resignation of Alejandro Galindo as Executive Vice President – Endocrine Business Unit, Effective October 21, 2022

MannKind Corporation Successfully Completes Phase 1 Study of Inhaled Clofazimine

Mannkind Corporation: Ready For Your Biotech Portfolio

New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed

MannKind Corporation to Report Q2, 2022 Results on Aug 09, 2022

MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™

Price target decreased to US$5.50

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

Consensus estimates of losses per share improve by 15%

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

High number of new directors

MannKind Corporation, Annual General Meeting, May 10, 2022

Consensus revenue estimates fall by 12%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

MannKind Corporation Provides Update on Tyvaso DPI New Drug Application

MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?

MannKind Corporation to Report Q4, 2021 Results on Feb 24, 2022

MannKind: A Promising Player In The Inhalable Insulin Market